Opsonophagocytosis versus lectinophagocytosis in human milk macrophages.
Some important immunoprotective effects of human breast milk have been attributed to the presence of macrophages. We investigated the generation of superoxide anion (O2-) by monocytes and human milk macrophages after stimulation with opsonized and unopsonized zymosan in the absence and presence of mannose as an inhibitor to investigate lectinophagocytic and opsonophagocytic properties. Peripheral blood monocytes generated more O2- than human milk macrophages (417,4 + 79,1 nmol O2-/mg protein vs. 216,1 +/-15,1 nmol O2-/mg protein, p<0,05) after stimulation with opsonized zymosan. When unopsonized zymosan was used as a serum-independent stimulus monocytes generated slightly less O2- in comparison to human milk macrophages (150,8 +/- 34,5 nmol/mg protein vs. 176,1 +/- 18 nmol O2-/mg protein, p<0,05). These findings demonstrate that the proportion of opsonin-independent phagocytosis in human milk macrophages is higher than in monocytes (82% vs. 36%). When mannose was used as an inhibitor a significantly higher reduction of O2- generation occurred in human milk macrophages compared to monocytes stimulated with opsonized zymosan, whereas no difference was found when unopsonized zymosan was used. These results indicate that human milk macrophages are stimulated to a greater extent by opsonin-independent mechanisms than blood borne monocytes. As the colostrum and the intestinal environment of the neonate offers only a little amount of opsonins like complement and immunoglobulin G, such a differentiation to lectinophagocytic properties could bear a great advantage for protective functions of human milk macrophages.
Schroten
H
H
University Children's Hospital, Heinrich Heine Universität Düsseldorf, Germany.
Kuczera
F
F
Köhler
H
H
Adam
R
R
D000276:Adjuvants, Immunologic; D002452:Cell Count; D005260:Female; D006801:Humans; D037102:Lectins / Q000276:immunology; D037181:Lectins, C-Type; D008264:Macrophages / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D008358:Mannose / Q000494:pharmacology; D000090323:Mannose Receptor; D037241:Mannose-Binding Lectins; D008895:Milk, Human / Q000166:cytology / Q000276:immunology*; D009000:Monocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D009895:Opsonin Proteins / Q000276:immunology; D010587:Phagocytosis / Q000187:drug effects; D011956:Receptors, Cell Surface / Q000378:metabolism; D013481:Superoxides / Q000302:isolation & purification / Q000378:metabolism*; D015054:Zymosan / Q000008:administration & dosage
D000276:Adjuvants, Immunologic; D037102:Lectins; D037181:Lectins, C-Type; D000090323:Mannose Receptor; D037241:Mannose-Binding Lectins; D009895:Opsonin Proteins; D011956:Receptors, Cell Surface; D013481:Superoxides; D015054:Zymosan; D008358:Mannose